Printer Friendly

RML EXPANDS CANCER TREATMENT CLINICAL TRIALS

 RML EXPANDS CANCER TREATMENT CLINICAL TRIALS
 TORONTO, July 16 /PRNewswire/ -- RML Medical Laboratories Inc. today


announced a significant expansion of its Phase II clinical trials with VIRULIZIN(TM) in the treatment of cancer.
 Since May 1992, RML has expanded to 11 the number of Phase II clinical trials currently under way at North American hospitals. During the past six months, patient enrollment has increased by over 50 percent. Over the next 12 to 18 months, the company plans to double the number of cancer centers participating in clinical trials with VIRULIZIN, more than double the number of Phase II clinical trials under way, and substantially increase patient enrollment. As previously announced, RML also intends to pursue regulatory approval to commence clinical trials in the United States and Europe.
 "The expansion is the result of recommendations from our clinical trial investigators," said Dr. Phil Gold, the cancer research specialist who chairs the company's medical advisory board. "And we have continued to receive expressions of interest from other hospitals and potential new investigators who wish to participate in our expanding clinical trial program as we move forward."
 The clinical trails with VIRULIZIN are focused on recurrent and metastatic melanoma, cancer of the pancreas and kidney, recurrent stomach, rectum and colon cancer. There is currently no effective treatment for these types of cancer.
 "Wherever possible, we intend to take advantage of opportunities for accelerated consideration of drugs designed to treat serious or life threatening diseases," said Richard A. Potts, president of the company.
 On Aug. 24, RML shareholders will be asked to approve a change in the company's name to IMUTEC Corporation. Shares and warrants trade on the Canadian Dealer Network and on the NASDAQ exchange.
 -0- 7/16/92
 /CONTACT: David W. Cooke, 416-724-1100, or 800-561-9400, or fax, 416-724-1167/
 (RMLBF) CO: RML Medical Laboratories Inc. ST: Ontario IN: MTC SU:


CK -- NY029 -- 9937 07/16/92 10:24 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 16, 1992
Words:317
Previous Article:BELIZE HOLDINGS REPORTS ANOTHER YEAR OF RECORD ACHIEVEMENT AND DEVELOPMENT
Next Article:FIRST MIDWEST BANCORP REPORTS SECOND QUARTER EARNINGS
Topics:


Related Articles
REITER APPOINTED RML DIRECTOR
RML FILES FINAL PROSPECTUS
Vertex and BioChem Advance Phase II Clinical Development of Cancer Multidrug Resistance Inhibitor, VX-710, in U.S. and Canada
CEL-SCI Corporation Starts New Cancer Trial in Canada
CEL-SCI Corporation Expands Clinical Trial for Cancer in Canada
Glycodesign Launches Phase II Trial for Promising New Cancer Drug
Aronex Pharmaceuticals Reports Responses Using ATRAGEN(R) as a Treatment for Non-Hodgkin's Lymphoma.
Aronex Pharmaceuticals Assumes Investigational New Drug Application For Aroplatin(TM).
Positive clinical data advances StressGen's HspE7 to phase III in anal dysplasia.
Calydon Announces Issuance of Three Patents for Technologies That Destroy Cancer Tumors, Including Prostate Cancer.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters